RESUMO
Hemangioblastoma (HB), a rare neoplasm of uncertain histogenesis, is characterized histologically by the presence of vacuolated; lipid-containing cells 'stromal cells' and a well developed, fine capillary network. Stromal cells are the neoplastic component of this tumor. Five-um sections were stained using streptavidin- biotin immunoperoxidase and immunofluorescent techniques. The stromal cells were uniformly "HIF-1α, Galectin-3, VEGF, VEGFR, WT-1, and bcl2," positive. Endothelial cells but not stromal cells were uniformly immunoreactive to CD31. Co-localization of HIF-1α with galectin-3 and VEGF as well as galectin-3 with VEGF in stromal cells is confirmed by immunofluorescent technique. In conclusion, the development of HB is multi-factorial and the expression of galectin-3 correlates with the expression of HIF-1α and VEGF. Galectin-3 can be used as a marker for the diagnosis of HB as well as it can be a valuable candidate for future targeting immunotherapy.
Assuntos
Biomarcadores Tumorais/análise , Neoplasias Cerebelares/metabolismo , Galectina 3/biossíntese , Hemangioblastoma/metabolismo , Proteínas Sanguíneas , Imunofluorescência , Galectina 3/análise , Galectinas , Humanos , Imuno-HistoquímicaRESUMO
Bronchioloalveolar carcinoma (BAC) is a subset of lung adenocarcinoma that has a distinct clinical presentation, tumor biology, response to therapy, and prognosis compared with other subtypes of non-small-cell lung carcinoma. BAC disproportionately affects women, never-smokers, and is characterized by growth along alveolar septae without evidence of stromal, vascular, or pleural invasion. Microscopically, BACs have been divided into mucinous, nonmucinous, and mixed types. We describe a case of young female who received radiation therapy to the mediastinum and chemotherapy for Hodgkin lymphoma and now develops mucinous bronchioalveolar adenocarcinoma of the left lung which to the best of our knowledge has not been previously described after radiotherapy and chemotherapy for Hodgkin lymphoma. The tumor cells express Galectin-3, CD138, p16INK4a, thyroid transcription factor-1, cytokeratin 7, epithelial membrane antigen, carcinoembryonic antigen, E-cadherin, neuron-specific enolase, and S100 whereas no expression of cytokeratin 20, calretinin, and CDX2 is seen.
Assuntos
Adenocarcinoma Mucinoso/metabolismo , Inibidor p16 de Quinase Dependente de Ciclina/biossíntese , Galectina 3/biossíntese , Doença de Hodgkin/metabolismo , Neoplasias Pulmonares/metabolismo , Proteínas de Neoplasias/biossíntese , Segunda Neoplasia Primária/metabolismo , Proteínas Nucleares/biossíntese , Sindecana-1/biossíntese , Fatores de Transcrição/biossíntese , Adenocarcinoma Mucinoso/patologia , Adenocarcinoma Mucinoso/terapia , Adulto , Feminino , Doença de Hodgkin/patologia , Doença de Hodgkin/terapia , Humanos , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/terapia , Segunda Neoplasia Primária/patologia , Segunda Neoplasia Primária/terapia , Fator Nuclear 1 de TireoideRESUMO
A 2-year-old boy presented with an abdominal mass and was diagnosed as Churg-Strauss syndrome (CSS). There was no history of asthma. He developed fatal gastro-intestinal disease, despite treatment with corticosteroids and cyclophosphamide. CSS is extremely rare in young children and gastro-intestinal involvement might carry a worse prognosis than in adults.